High-performance proteins at the speed of mRNA.
Boost’s Rapid Antigen Deployment (RAD™) platform builds protein antigens, vaccines, and monoclonal antibodies against the world’s most dangerous pathogens — engineered to be safe, potent, scalable, stable, and low-cost.
Phase 1 lead SARS-CoV-2 program · data mid-2026.
Backed by the institutions that define pandemic preparedness.
The world's leading pandemic preparedness and biomedical research institutions — including the Coalition for Epidemic Preparedness Innovations (CEPI), the National Institutes of Health / National Institute of Allergy and Infectious Disease (NIH/NIAID), and the Center for the Biomedical Advanced Research and Development Authority (BARDA) — support Boost’s work developing new vaccines and monoclonal antibodies.
The company is also supported by dedicated and knowledgeable investors.
We're building a company that responds to global health needs with safety, efficacy, speed, and cost in mind. If that's a vision you share — as an investor, partner, or collaborator — let's talk.